Triumvira Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 49

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $100M

  • Investors
  • 13

Triumvira General Information

Description

Developer of immunotherapy-based drugs designed to provide novel T-cell therapies for cancer treatment. The company's technology recruits the entire natural T-cell receptor and functions independent of the major histocompatibility complex, potentially permitting the development of improved therapies for a broad range of patients with solid or liquid malignancies and with diseases other than cancer, enabling medical practitioners and patients with hope to deal with life-threatening diseases.

Contact Information

Website
www.triumvira.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 175 Longwood Road South
  • Suite 305
  • Hamilton, Ontario L8P 0A1
  • Canada
+1 (201) 000-0000
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Vertical(s)
LOHAS & Wellness, Life Sciences, Oncology
Corporate Office
  • 175 Longwood Road South
  • Suite 305
  • Hamilton, Ontario L8P 0A1
  • Canada
+1 (201) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Triumvira Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series A) 21-Sep-2022 $100M 00000 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series A) 27-Aug-2020 0000 0000 Completed Clinical Trials - Phase 1
4. Debt Repayment 16-Apr-2020 000 0000 Completed Clinical Trials - Phase 1
3. Debt - General 20-Feb-2019 000 0000 Completed Clinical Trials - Phase 1
2. Early Stage VC $8M $8M Completed Startup
1. Grant $5M Completed Startup
To view Triumvira’s complete valuation and funding history, request access »

Triumvira Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immunotherapy-based drugs designed to provide novel T-cell therapies for cancer treatment. The company's te
Drug Discovery
Hamilton, Canada
49 As of 2024
00000
00000000000 00000

0000 0

e velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cup
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

000000

uat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolor
0000000000000
Gaithersburg, MD
00 As of 0000
00000
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Triumvira Competitors (33)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
NexImmune Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
Sorrento Therapeutics Formerly VC-backed San Diego, CA 000 00000 0000000000.
Cellerant Therapeutics Venture Capital-Backed Newark, CA 0 000.00 00000000000 000.00
Eureka Therapeutics Venture Capital-Backed Emeryville, CA 00 00000 0000000000 0 00000
You’re viewing 5 of 33 competitors. Get the full list »

Triumvira Executive Team (15)

Name Title Board Seat
Paul Lammers MD President, Chief Executive Officer & Board Member
Robert Williamson III President, Board Member & Chief Operating Officer
Donna Rill Chief Technology Officer
Andreas Bader Ph.D Consulting Chief Scientific Officer
Christopher Helsen Ph.D Co-Founder, Director Research and Development & Head of Platform Development
You’re viewing 5 of 15 executive team members. Get the full list »

Triumvira Board Members (16)

Name Representing Role Since
Brian Bloom Self Co-Founder & Board Observer 000 0000
Connor McDermott Northpond Ventures Board Member 000 0000
Elizabeth Williams Self Board Member 000 0000
Jonathan Bramson Ph.D Triumvira Scientific Co-Founder & Chairman of Scientific Advisory Counsel 000 0000
Jürgen Eckhardt MD Leaps by Bayer Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Triumvira Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Triumvira Investors (13)

Investor Name Investor Type Holding Investor Since Participating Rounds
ATEM Capital Venture Capital Minority 000 0000 000000 0
Bayer Corporation Minority 000 0000 000000 0
B Capital Group Venture Capital Minority 000 0000 000000 0
Hibiscus Capital Management Venture Capital Minority 000 0000 000000 0
Myeloma Investment Fund Not-For-Profit Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 13 investors. Get the full list »

Ready to get started?

Request a free trial

Triumvira FAQs

  • When was Triumvira founded?

    Triumvira was founded in 2015.

  • Who is the founder of Triumvira?

    Christopher Helsen Ph.D, Jonathan Bramson Ph.D, and Brian Bloom are the founders of Triumvira.

  • Who is the CEO of Triumvira?

    Paul Lammers MD is the CEO of Triumvira.

  • Where is Triumvira headquartered?

    Triumvira is headquartered in Hamilton, Canada.

  • What is the size of Triumvira?

    Triumvira has 49 total employees.

  • What industry is Triumvira in?

    Triumvira’s primary industry is Drug Discovery.

  • Is Triumvira a private or public company?

    Triumvira is a Private company.

  • What is Triumvira’s current revenue?

    The current revenue for Triumvira is 00000.

  • How much funding has Triumvira raised over time?

    Triumvira has raised $168M.

  • Who are Triumvira’s investors?

    ATEM Capital, Bayer, B Capital Group, Hibiscus Capital Management, and Myeloma Investment Fund are 5 of 13 investors who have invested in Triumvira.

  • Who are Triumvira’s competitors?

    Aura Biosciences, NexImmune, Sorrento Therapeutics, Cellerant Therapeutics, and Eureka Therapeutics are some of the 33 competitors of Triumvira.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »